Price
Frequently asked questions
What is Incyte's market capitalization?
What is Incyte's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Incyte?
What are the analyst ratings and target price for Incyte's stock?
What is Incyte's revenue over the trailing twelve months?
What is the EBITDA for Incyte?
What is the free cash flow of Incyte?
What is the 5-year beta of Incyte's stock?
How many employees does Incyte have, and what sector and industry does it belong to?
What is the free float of Incyte's shares?
Financials
Market Cap
$14.24B5Y beta
0.73EPS (TTM)
$0.14Free Float
188.68MP/E ratio (TTM)
528.26Revenue (TTM)
$4.08BEBITDA (TTM)
$107.68MFree Cashflow (TTM)
$30.70MPricing
Analyst Ratings
The price target is $71.44 and the stock is covered by 22 analysts.
Buy
10
Hold
11
Sell
1
Information
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
2,524
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker